ImmunityBio Inc (IBRX) concluded trading on Tuesday at a closing price of $2.63, with 2.02 million shares of worth about $5.3 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -61.15% during that period and on December 24, 2024 the price saw a loss of about -1.50%. Currently the company’s common shares owned by public are about 696.83M shares, out of which, 44.67M shares are available for trading.
Stock saw a price change of -7.07% in past 5 days and over the past one month there was a price change of -48.43%. Year-to-date (YTD), IBRX shares are showing a performance of -47.61% which decreased to -40.77% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.50 but also hit the highest price of $10.53 during that period. The average intraday trading volume for ImmunityBio Inc shares is 6.15 million. The stock is currently trading -31.41% below its 20-day simple moving average (SMA20), while that difference is down -40.49% for SMA50 and it goes to -49.32% lower than SMA200.
ImmunityBio Inc (NASDAQ: IBRX) currently have 696.83M outstanding shares and institutions hold larger chunk of about 9.44% of that.
The stock has a current market capitalization of $1.89B and its 3Y-monthly beta is at 0.69. It has posted earnings per share of -$0.89 in the same period. It has Quick Ratio of 2.64. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IBRX, volatility over the week remained 5.97% while standing at 7.41% over the month.
Stock’s fiscal year EPS is expected to rise by 27.54% while it is estimated to increase by 19.20% in next year. EPS is likely to shrink at an annualized rate of -1.70% for next 5-years, compared to annual growth of 1.17% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on May 12, 2023 offering a Neutral rating for the stock and assigned a target price range of between $10 and $4 to it. Coverage by Jefferies stated ImmunityBio Inc (IBRX) stock as a Buy in their note to investors on August 03, 2022, suggesting a price target of $8 for the stock.
